Is Glaxo's China Nightmare Finally Ending?

By Dave Williamson and Alison Southwick – Nov 10, 2013 at 9:00PM

NYSE: GSK

GSK

Market Cap

$88B

Today's Change

(0.35%) $0.15

Current Price

$43.50

Price as of May 3, 2024, 4:00 p.m. ET

Could GlaxoSmithKline finally be off the hook in China?

From the smallest biotech to the biggest pharmaceutical stock The Motley Fool's Market Check-Up covers the health-care sector's biggest headlines, hottest market movers, and Obamacare's ongoing rollout.

In this segment, health-care analyst David Williamson looks into GlaxoSmithKline (GSK 0.35%) and the recent allegations of widespread corruption plaguing the company in China. David looks at an article from Reuters reporting that some of the company's executives may be charged, but it's unlikely that the company itself will be. David also examines how badly sales have suffered under the shadow of these allegations, and how much of an impact Chinese sales have on the bigger picture for GlaxoSmithKline.

Alison Southwick and David Williamson have no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid.

The Motley Fool has no position in any of the stocks mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.